Dexcom develops continuous glucose monitoring (CGM) systems that measure interstitial glucose in real time for people with diabetes. Its wearable sensors and companion apps reduce the need for fingerstick tests and support insulin dosing decisions for patients and clinicians. The company is widely associated with consumer CGM devices such as the G6 and G7 platforms used in outpatient diabetes care.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 1,036 | — | 105.4 | -14.6% |
| Q2 2025 | 1,157.1 | — | 179.8 | 5.1% |
| Q3 2025 | 1,209.3 | — | 283.8 | 56.8% |
| Q4 2025 | 1,259.6 | — | 267.3 | 52.1% |
| Q1 2026 | 1,191.9 | 15.1% | 199.5 | 89.3% |
| Q2 2026 | 1,308.4 | 13.1% | 249.1 | 38.5% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Credo Technology Group Holding Ltd (CRDO), Axon Enterprise, Inc. (AXON), GE HealthCare Technologies Inc. (GEHC), Cognizant Technology Solutions Corporation (CTSH), United Airlines Holdings, Inc. (UAL), Alnylam Pharmaceuticals, Inc. (ALNY)